{
  "id": "mhgap#risk_safety_42132da1",
  "content": "Recommendation (new): Selective serotonin reuptake inhibitors (SSRIs) should be considered for\nadults with panic disorder. If SSRIs are not available, consider offering\ntricyclic antidepressants (TCAs). SSRIs should be considered for adults with\ngeneralized anxiety disorder (GAD).\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification based on limited data and should be interpreted\ny Evidence was included from two meta-analyses: with caution.\nChawla et al., 2022 (87 RCTs on pharmacological y TCAs for panic disorder examined included\ninterventions for panic disorder) (33); and Slee et al., imipramine and clomipramine.\n2019 (89 RCTs on pharmacological interventions for y SSRIs for GAD examined included citalopram,\nGAD) (34). escitalopram, fluoxetine, paroxetine and sertraline.\ny Low-quality evidence suggested reduced levels of Paroxetine was the only SSRI that demonstrated\nanxiety symptoms in adults with GAD and panic increased risk of adverse events (dropout) relative to\ndisorder using antidepressants (TCAs or SSRIs). Very placebo.\nlow-quality evidence suggested reduced levels of y Evidence on the use of TCAs (imipramine) for GAD\nanxiety symptoms in adults with anxiety disorders was limited and indicated they did not demonstrate\n(GAD or panic disorder) using either psychological a significant effect relative to placebo.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety Recommendation (new): Selective serotonin reuptake inhibitors (SSRIs) should be considered for\nadults with panic disorder. If SSRIs are not available, consider offering\ntricyclic antidepressants (TCAs). SSRIs should be considered for adults with\ngeneralized anxiety disorder (GAD).\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification based on limited data and should be interpreted\ny Evidence was included from two meta-analyses: with caution.\nChawla et al., 2022 (87 RCTs on pharmacological y TCAs for panic disorder examined included\ninterventions for panic disorder) (33); and Slee et al., imipramine and clomipramine.\n2019 (89 RCTs on pharmacological interventions for y SSRIs for GAD examined included citalopram,\nGAD) (34). escitalopram, fluoxetine, paroxetine and sertraline.\ny Low-quality evidence suggested reduced levels of Paroxetine was the only SSRI that demonstrated\nanxiety symptoms in adults with GAD and panic increased risk of adverse events (dropout) relative to\ndisorder using antidepressants (TCAs or SSRIs). Very placebo.\nlow-quality evidence suggested reduced levels of y Evidence on the use of TCAs (imipramine) for GAD\nanxiety symptoms in adults with anxiety disorders was limited and indicated they did not demonstrate\n(GAD or panic disorder) using either psychological a significant effect relative to placebo. Recommendation (new): selective serotonin reuptake inhibitors (ssris) should be considered for\nadults with panic disorder. if ssris are not available, consider offering\ntricyclic antidepressants (tcas)."
}